Trial Profile

Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Feb 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
17 Apr 2023 According to Regeneron Pharmaceuticals media release, data from this study will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
08 Feb 2023 According to Regeneron Pharmaceuticals media release, the company has received an approval for aflibercept injection from the U.S. FDA to treat preterm infants with retinopathy of prematurity. The FDA approval is suppoted by the data from this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com